Please find attached the file
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories' Board approved a second addendum to the Business Transfer Agreement with subsidiary Morepen Medipath Limited, revising the appointed date for transfer of Medical Devices Business to April 1, 2026 at a slump sale consideration of Rs. 19,710.12 lakhs. The company also approved audited FY2026 standalone results showing revenue of Rs. 1,702.69 crore and net profit of Rs. 66.06 crore (vs Rs. 101.58 crore in FY2025), and consolidated results with revenue of Rs. 1,827.01 crore and net profit after minority interest of Rs. 20.32 crore (down from Rs. 118.02 crore, impacted by exceptional items and loss of control of Dr. Morepen subsidiary from July 31, 2025). The Board recommended a final dividend of Rs. 0.20 per equity share. Statutory auditors issued an unmodified opinion on both standalone and consolidated financial statements.
The FY2026 standalone profit decline of ~35% year-on-year reflects challenging operating conditions. The Medical Devices business transfer to subsidiary is progressing after delays in obtaining statutory approvals. The dividend at Rs. 0.20 per share is modest but signals Board confidence. Shareholders should note the pending cancellation of 50,62,872 equity shares per NCLT order.